PubMed: Szakterületek: Purpose: To compare the efficacy of perioperative treatment strategies, in addition to topical bromfenac 0. Setting: Twelve European study centers.
Design: Randomized clinical trial. Methods: Diabetic patients having phacoemulsification cataract surgery were randomly allocated to receive no additional treatment, a subconjunctival injection with 40 mg triamcinolone acetonide, an intravitreal injection with 1. The main outcomes were the difference in central subfield mean macular thickness, corrected distance visual acuity, and the incidence of CME and clinically significant macular edema within 6 and 12 weeks postoperatively.
Results: The study comprised patients. At 6 and 12 weeks postoperatively, the central subfield mean macular thickness was No patient who received subconjunctival triamcinolone acetonide developed CME. Intravitreal bevacizumab had no significant effect on macular thickness. Conclusions: Diabetic patients who received a subconjunctival injection with triamcinolone acetonide at the end of cataract surgery had a lower macular thickness and macular volume at 6 and 12 weeks postoperatively than patients who did not.
Intravitreal bevacizumab had no significant effect.